Sellas Life Sciences Group Inc (SLS) Stock Price, Quote & News

Company Profile

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is adm...

Industry: Biotechnology

Sector: Healthcare

Phone: 646 200 5278

Website: www.sellaslifesciences.com

Address:

7 Times Square, Suite 2503, New York, United States

mikeyakamike1 Feb. 4 at 3:18 AM

$SLS Onwards and upwards.

0 · Reply

LennyTheBull Feb. 4 at 3:18 AM

$SLS “We will announce the 80th event upon occurrence to trigger the final analysis.” - Sterg Translation: • No delays • No protocol changes • No “IDMC guidance” ambiguity • Clean, binary readout once the 80th person passes This suggests operational confidence and no safety or futility concerns. Bottom line, if he wasn’t confident, this post would not exist.

0 · Reply

samsha1 Feb. 4 at 3:15 AM

$SLS 🚀 $SLS – The AbbVie / $ABBV VEN Synergy The Strategy • GPS (WT-1 Vaccine): Phase 3 REGAL final OS data imminent (72/80 events). Goal = durable remission → functional dormancy • SLS009 (CDK9): Suppresses MCL-1 survival signaling → clean, mechanistic plug-and-play with VEN The Catalyst • True synergy: SLS009 shows activity in ASXL1-mutated AML (VEN-resistant population) • Seamless integration: Drops directly onto AZA/VEN backbone — no paradigm shift, no retraining Big Picture • GPS maintains disease control • SLS009 + VEN eliminates residual disease • Together = full-stack AML architecture Bottom Line • Purpose-built for AbbVie-scale expansion or acquisition 🧪🔥

0 · Reply

mchansen7 Feb. 4 at 3:15 AM

$SLS

0 · Reply

YEHMINGZHU Feb. 4 at 3:05 AM

$SLS primary completion date estimated as end of 2025. Also clinical trials did now update to year end 2026 but thats just paperwork stuff it can end anytime. We are now in Feb 2026. The trial is overdue and that is very rare for AML trials.. AML is incredibly aggressive. And again the patients are CR2 you can not artificially keep them alive with extra better supportive care like antibiotics or other off label drugs these are very sick people who have relapsed once. You need a potent drug to push this farther... you really dont need much else to be bullish here than being overdue which is insanely bullish and nothing refutes this. BAT arm is not the one pushing this longer. Compare it to slow moving cancers like prostate.. a 3 month delay is nothing. Aml is week long timelines usually and this delay is significant. Bears have no clue what they are shorting here.. so yeah im bullish. We all know whats happening here BP.. we're not selling

0 · Reply

RealImbackbears Feb. 4 at 2:58 AM

$SLS where is my boy gps_100x the paid pumper and short seller who gets cheap warrants for writing seeking Alpha articles GPS Doa

0 · Reply

RealImbackbears Feb. 4 at 2:58 AM

$SLS Based on common issues with Stocktwits and similar social platforms, it is likely a, technical, caching, or display error where your "Join Date" is not rendering correctly, or a, system update has defaulted your profile date. Here is what you should check: Platform Bug/System Glitch: Stocktwits sometimes experiences display errors, particularly if they have pushed a new design or if your profile data is not loading correctly from their database. Similar issues have happened on other platforms where old accounts suddenly show a new date

0 · Reply

Szepen Feb. 4 at 2:50 AM

$SLS I think an upward pressure on SP will start from now until 80th event...what about $1/month?

1 · Reply

Abtr Feb. 4 at 2:40 AM

$SLS From our Ceo.

0 · Reply

lowernashotah Feb. 4 at 2:35 AM

$SLS "Next: We will announce the 80th event upon occurrence to trigger the final analysis." — Sterg

4 · Reply

SELLAS Life Sciences Enters Agreement with IMPACT-AML to Expand SLS009 Clinical Program into Europe

Dec 29, 2025, 8:35 AM EST - 5 weeks ago

SELLAS Life Sciences Provides Update on Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML)

$SELLAS Life Sciences Presents Positive Phase 2 Data of SLS009 in Combination with AZA/VEN in Relapsed/Refractory AML-MR at ASH 2025$

Dec 7, 2025, 6:00 PM EST - 2 months ago

SELLAS Life Sciences Presents Positive Phase 2 Data of SLS009 in Combination with AZA/VEN in Relapsed/Refractory AML-MR at ASH 2025

Oct 29, 2025, 5:36 PM EDT - 3 months ago

SELLAS Life Sciences Group, Inc. (SLS) Discusses Innovation in AML Treatments With Focus on GPS and SLS009 Programs Transcript

Oct 27, 2025, 8:30 AM EDT - 3 months ago

SELLAS Life Sciences Group Announces Exercise of Existing Warrants Held by a Current Institutional Investor for $31 Million in Gross Proceeds

Aug 19, 2025, 9:18 PM EDT - 6 months ago

Sellas Life Sciences: SLS009's Phase 2 Sets Up A Promising 2026

Aug 7, 2025, 8:30 AM EDT - 6 months ago

SELLAS Life Sciences Announces Independent Data Monitoring Committee Periodic Review and Positive Recommendation to Continue Pivotal Phase 3 REGAL Trial of GPS in AML Without Modification

Jul 7, 2025, 8:45 AM EDT - 7 months ago

SELLAS Life Sciences Appoints Linghua Wang, MD, PhD, to Scientific Advisory Board

Jun 5, 2025, 8:45 AM EDT - 8 months ago

SELLAS Life Sciences Expands Scientific Advisory Board with Addition of Two World-Renowned Hematology and Oncology Experts

Jun 2, 2025, 8:00 AM EDT - 8 months ago

SELLAS Presents Preclinical Efficacy of SLS009 in ASXL1 Mutated Colorectal Cancer at 2025 ASCO Annual Meeting

May 20, 2025, 8:00 AM EDT - 9 months ago

SELLAS Life Sciences to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company Showcase

May 15, 2025, 8:45 AM EDT - 9 months ago

SELLAS Life Sciences Announces First Pediatric AML Patient Dosed in the Ongoing Phase 2 Trial of SLS009 r/r AML

May 13, 2025, 4:05 PM EDT - 9 months ago

SELLAS Life Sciences Reports First Quarter 2025 Financial Results and Provides Corporate Update

Apr 28, 2025, 8:45 AM EDT - 10 months ago

SELLAS Unveils Breakthrough Preclinical Data Highlighting Efficacy of SLS009 in TP53 Mutated AML at the 2025 AACR Conference

Apr 23, 2025, 10:23 AM EDT - 10 months ago

SELLAS to Present at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 8, 2025, 8:45 AM EDT - 10 months ago

SELLAS Announces Positive Overall Survival in Cohort 3 from the Ongoing Phase 2 Trial of SLS009 in r/r AML

Mar 31, 2025, 3:03 PM EDT - 11 months ago

Sellas Life Sciences: A Hold For Now With Huge, But Uncertain, Near-Term Catalyst

Mar 20, 2025, 4:05 PM EDT - 11 months ago

SELLAS Life Sciences Reports Full Year 2024 Financial Results and Provides Corporate Update

Feb 20, 2025, 8:45 AM EST - 1 year ago

SELLAS Announces Positive Data from Phase 2a Trial of SLS009 in Combination with Zanubrutinib in DLBCL

Jan 28, 2025, 3:11 PM EST - 1 year ago

SELLAS Life Sciences Group Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 23, 2025, 8:10 AM EST - 1 year ago

SELLAS Life Sciences Announces Positive Outcome of Interim Analysis for its Pivotal Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia

Jan 8, 2025, 8:20 AM EST - 1 year ago

SELLAS Announces Key Business Objectives for 2025

Dec 10, 2024, 8:30 AM EST - 1 year ago

SELLAS Life Sciences Triggers Interim Analysis in Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia

Dec 9, 2024, 8:45 AM EST - 1 year ago

SELLAS Announces Positive Overall Survival and Overall Response Rate Data from the Phase 2 Trial of SLS009 in r/r AML

Nov 27, 2024, 8:45 AM EST - 1 year ago

SELLAS Announces Positive Data from Preclinical Studies Indicating ASXL1 Mutations as Predictor of Response to SLS009 in Solid Cancers

Nov 13, 2024, 4:15 PM EST - 1 year ago

SELLAS Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 13, 2024, 8:00 AM EST - 1 year ago

voxeljet, Dressler Group GmbH, Fraunhofer IPA and the University of Bayreuth Collaborate in Re-Processing of Discarded PA12 Powder for 3D Printing via High-Speed Sintering (HSS)

Nov 5, 2024, 9:55 AM EST - 1 year ago

SELLAS Life Sciences to Present at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition 2024

Oct 15, 2024, 8:45 AM EDT - 1 year ago

SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to Galinpepimut-S (GPS) for the Treatment of Pediatric Acute Myeloid Leukemia

Oct 10, 2024, 4:05 PM EDT - 1 year ago

SELLAS Life Sciences to Participate in Fireside Chat at the 2024 Maxim Healthcare Virtual Summit

Aug 13, 2024, 4:10 PM EDT - 1 year ago

SELLAS Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 6, 2024, 8:45 AM EDT - 1 year ago

SELLAS Receives EMA Orphan Drug Designation for SLS009 for Treatment of Peripheral T-cell Lymphomas

Jul 16, 2024, 9:05 AM EDT - 1 year ago

SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to SLS009 for the Treatment of Pediatric Acute Myeloid Leukemia

Jul 8, 2024, 8:45 AM EDT - 1 year ago

SELLAS Receives European Medicines Agency Orphan Drug Designation for SLS009 for the Treatment of Acute Myeloid Leukemia

Jun 24, 2024, 9:05 AM EDT - 1 year ago

SELLAS Announces U.S. FDA Rare Pediatric Disease Designation Granted to SLS009 for the Treatment of Pediatric Acute Lymphoblastic Leukemia

Jun 17, 2024, 9:05 AM EDT - 1 year ago

SELLAS Life Sciences Announces Positive Recommendation from the Independent Data Monitoring Committee of the Phase 3 REGAL Trial in Acute Myeloid Leukemia

Jun 10, 2024, 8:40 AM EDT - 1 year ago

SELLAS Announces Completion of Enrollment and Initial Positive Data in Phase 2a Trial of SLS009 in r/r AML

May 14, 2024, 4:05 PM EDT - 1 year ago

SELLAS Life Sciences Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 1, 2024, 8:35 AM EDT - 1 year ago

SELLAS Announces Positive Phase 2 Preliminary Data of SLS009 in r/r AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation At the Optimal Dose Level

Apr 29, 2024, 8:45 AM EDT - 1 year ago

SELLAS Life Sciences Announces Positive Recommendation of Independent Data Monitoring Committee Following Completion of Enrollment in REGAL Phase 3 Study

Apr 19, 2024, 1:49 PM EDT - 1 year ago

Sellas Life Sciences Group: A Lottery Ticket With An Estimated 9x Payout

Mar 28, 2024, 4:05 PM EDT - 2 years ago

SELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate Update

Mar 26, 2024, 7:35 AM EDT - 2 years ago

SELLAS Announces Positive Topline Data from the Phase 2a Study of SLS009 in r/r AML and Provides Steering Committee Update on Phase 3 REGAL Study

Mar 19, 2024, 4:05 PM EDT - 2 years ago

SELLAS Life Sciences Group Announces Closing of $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

Mar 19, 2024, 8:47 AM EDT - 2 years ago

SELLAS Life Sciences to Host Corporate Update Call on March 26, 2024, at 8:15 am ET

Mar 15, 2024, 9:00 AM EDT - 2 years ago

SELLAS Life Sciences Group Announces $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

Mar 8, 2024, 8:00 AM EST - 2 years ago

SELLAS Announces Executive Leadership Reorganization and Prioritization of Commercialization Partnerships

Mar 1, 2024, 8:30 AM EST - 2 years ago

SELLAS Life Sciences Delivers Oral Presentation of SLS009 Phase 1 Data for Acute Myeloid Leukemia Patients at 2024 European School of Haematology (ESH) Conference

Feb 29, 2024, 8:00 AM EST - 2 years ago

SELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conference: Updated Date and Time

Feb 6, 2024, 8:30 AM EST - 2 years ago

SELLAS Announces Publication of Preclinical Data on its Highly Selective CDK9 Inhibitor, SLS009, in Oncotarget

mikeyakamike1 Feb. 4 at 3:18 AM

$SLS Onwards and upwards.

0 · Reply

LennyTheBull Feb. 4 at 3:18 AM

0 · Reply

samsha1 Feb. 4 at 3:15 AM

0 · Reply

mchansen7 Feb. 4 at 3:15 AM

$SLS

0 · Reply

YEHMINGZHU Feb. 4 at 3:05 AM

0 · Reply

RealImbackbears Feb. 4 at 2:58 AM

$SLS where is my boy gps_100x the paid pumper and short seller who gets cheap warrants for writing seeking Alpha articles GPS Doa

0 · Reply

RealImbackbears Feb. 4 at 2:58 AM

0 · Reply

Szepen Feb. 4 at 2:50 AM

$SLS I think an upward pressure on SP will start from now until 80th event...what about $1/month?

1 · Reply

Abtr Feb. 4 at 2:40 AM

$SLS From our Ceo.

0 · Reply

lowernashotah Feb. 4 at 2:35 AM

$SLS "Next: We will announce the 80th event upon occurrence to trigger the final analysis." — Sterg

4 · Reply

RealImbackbears Feb. 4 at 2:30 AM

$SLS who here has married this stock. Soon you will all be this old waiting for 5.00

3 · Reply

AnthonySaba79 Feb. 4 at 2:23 AM

$SLS just break 5 already.. simple

0 · Reply

Stock_Catcher Feb. 4 at 2:15 AM

Wealthy Wednesday Watchlist Pt 6 $ASTI $SIDU $SOPA $SLS $GORO Let's Find a 1000% Runner this week

0 · Reply

JdlawVT40 Feb. 4 at 2:13 AM

$SLS very reassuring update from the ceo. I am more confident in this investment than ever. Anyone betting against the potential bonanza here might think carefully of the odds.

0 · Reply

insidersruleloosersdrool Feb. 4 at 2:10 AM

$SLS Two world class Trials and drugs, $100 million in the bank, no debt, $4.00 per share, Twits is showing a $565 million market cap. A sudden repricing of shares will happen very soon. Be buckled in for the violent swing up. Sell for pennies if you want.

0 · Reply

SunnySeed Feb. 4 at 2:10 AM

$SLS IDMC WILL 100% halt this trial for overwhelming efficacy! Also where is Stergs bonus

2 · Reply

Kenny40000 Feb. 4 at 2:08 AM

$SLS so many potential takeaways from that investor update. The best part is, all of the negative ones are getting easier to refute. Skepticism won’t last too much longer around here. Can’t wait for the next few weeks

1 · Reply

Wefel Feb. 4 at 2:07 AM

$SLS May 08, 2025

0 · Reply

stockforce123 Feb. 4 at 2:02 AM

$SLS Sterg keeps saying “Next: We will announce the 80th event upon occurrence to trigger the final analysis.” This is just standard language. He even dares not give a guesstimate when this event might happen. Nobody will wait for that.

2 · Reply

mchansen7 Feb. 4 at 2:02 AM

$SLS this bearish sentiment has to be the biggest joke ever. Bears are working their tails off to keep it this way.

0 · Reply

Kgra Feb. 4 at 1:57 AM

$SLS the part that really sucks is that even with priority review , this is still prob 12-18 m out before it could start helping people assuming we don’t get to that 80 th event till summer unless trial is stopped early.

0 · Reply

Bayside1983 Feb. 4 at 1:57 AM

$SLS makes me think a deal is already done.

1 · Reply

Market Cap	537.01M
Revenue (ttm)	0.00
Net Income (ttm)	-30.88M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	4,619,000
Avg Vol	8,978,764
Day's Range	N/A - N/A
Shares Out	142.44M
Stochastic %K	42%
Beta	2.26
Analysts	Strong Sell
Price Target	$6.83